Anna Sureda1, Mei-Jie Zhang2,3, Peter Dreger4, Jeanette Carreras2, Timothy Fenske5, Herve Finel6, Harry Schouten7, Silvia Montoto8, Stephen Robinson9, Sonali M Smith10, Ariane Boumedil6, Mehdi Hamadani2, Marcelo C Pasquini2. 1. Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain. 2. Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. Universitaetsklinkum Heidelberg, Heidelberg, Germany. 5. Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. 6. Central Registry Office, European Society for Blood and Marrow Transplantation, Paris, France. 7. Department of Hematology, Academische Ziekenhuis, Maastricht, the Netherlands. 8. Department of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom. 9. University Hospitals Bristol NHS Trust, Bristol, United Kingdom. 10. Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
Abstract
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only potentially curative treatment option for relapsed follicular lymphoma (FL), yet questions remain about the optimal timing. This study analyzed long-term outcomes and associated factors among recipients of allo-HCT with FL. METHODS: Patients with relapsed FL who underwent allo-HCT from 2001 to 2011 with a human leukocyte antigen (HLA)-matched donor were included. Outcome analyses for overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and disease relapse/progression were calculated. A multivariate analysis was performed to determine factors associated with outcomes, and a prognostic score for treatment failure was developed in a subset analysis of patients. RESULTS: In all, 1567 patients with relapsed FL were included; the median follow-up was 55 months. The 5-year probabilities of OS and PFS were 61% and 52%, respectively. The 5-year cumulative incidences of disease progression/relapse and TRM were 29% and 19%, respectively. Chemoresistant disease, older age, heavy pretreatment, poor performance status (PS), and myeloablative protocols were predictors for worse survival. The prognostic score, using age, lines of prior therapy, disease status, and PS, stratified patients into 3 groups-low, intermediate, and high risk-with 5-year PFS rates of 68%, 53%, and 46%, respectively, and 5-year OS rates of 80%, 62%, and 50%, respectively. CONCLUSIONS: Allo-HCT should be considered for patients with relapsed FL and available HLA-matched donors. Outcomes are better in earlier phases of the disease, and reduced-intensity conditioning should be preferred. The prognostic score presented here can assist in counseling patients and determining the time to proceed to transplantation. Cancer 2018;124:1733-42.
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only potentially curative treatment option for relapsed follicular lymphoma (FL), yet questions remain about the optimal timing. This study analyzed long-term outcomes and associated factors among recipients of allo-HCT with FL. METHODS:Patients with relapsed FL who underwent allo-HCT from 2001 to 2011 with a human leukocyte antigen (HLA)-matched donor were included. Outcome analyses for overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and disease relapse/progression were calculated. A multivariate analysis was performed to determine factors associated with outcomes, and a prognostic score for treatment failure was developed in a subset analysis of patients. RESULTS: In all, 1567 patients with relapsed FL were included; the median follow-up was 55 months. The 5-year probabilities of OS and PFS were 61% and 52%, respectively. The 5-year cumulative incidences of disease progression/relapse and TRM were 29% and 19%, respectively. Chemoresistant disease, older age, heavy pretreatment, poor performance status (PS), and myeloablative protocols were predictors for worse survival. The prognostic score, using age, lines of prior therapy, disease status, and PS, stratified patients into 3 groups-low, intermediate, and high risk-with 5-year PFS rates of 68%, 53%, and 46%, respectively, and 5-year OS rates of 80%, 62%, and 50%, respectively. CONCLUSIONS: Allo-HCT should be considered for patients with relapsed FL and available HLA-matched donors. Outcomes are better in earlier phases of the disease, and reduced-intensity conditioning should be preferred. The prognostic score presented here can assist in counseling patients and determining the time to proceed to transplantation. Cancer 2018;124:1733-42.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles Journal: N Engl J Med Date: 2014-01-22 Impact factor: 91.245
Authors: Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore Journal: Nat Med Date: 2013-01-06 Impact factor: 53.440
Authors: Ruth Pettengell; Norbert Schmitz; Christian Gisselbrecht; Graeme Smith; William N Patton; Bernd Metzner; Dolores Caballero; Herve Tilly; Jan A Walewski; Isabelle Bence-Bruckler; Bik To; Christian H Geisler; Rik Schots; Eva Kimby; Christian J Taverna; Tomás Kozák; Peter Dreger; Ruzena Uddin; Carmen Ruiz de Elvira; Anthony H Goldstone Journal: J Clin Oncol Date: 2013-04-01 Impact factor: 44.544
Authors: S P Robinson; A Boumendil; H Finel; H Schouten; G Ehninger; J Maertens; C Crawley; A Rambaldi; N Russell; W Anders; D Blaise; I Yakoub-Agha; A Ganser; L Castagna; L Volin; J-Y Cahn; S Montoto; P Dreger Journal: Ann Oncol Date: 2016-06-01 Impact factor: 32.976
Authors: S P Robinson; C Canals; J J Luang; H Tilly; C Crawley; J Y Cahn; D Pohlreich; S Le Gouill; M Gilleece; N Milpied; M Attal; P Biron; S Maury; A Rambaldi; J Maertens; S Capria; P Colombat; S Montoto; A Sureda Journal: Bone Marrow Transplant Date: 2013-06-17 Impact factor: 5.483
Authors: José Luis Piñana; Rodrigo Martino; Jorge Gayoso; Anna Sureda; Javier de la Serna; Jose Luis Díez-Martín; Lourdes Vazquez; Reyes Arranz; José Francisco Tomás; Antonia Sampol; Carlos Solano; Julio Delgado; Jorge Sierra; Dolores Caballero Journal: Haematologica Date: 2010-01-27 Impact factor: 9.941
Authors: Neeraj Y Saini; Rima M Saliba; Gabriela Rondon; Farzaneh Maadani; Uday Popat; Chitra M Hosing; Betul Oran; Qaiser Bashir; Amanda Olson; Yago Nieto; Amin Alousi; Partow Kebriaei; Samer Srour; Rohtesh Mehta; Paolo Anderlini; Elizabeth J Shpall; Muzaffar H Qazilbash; Issa F Khouri; Luis Fayad; Hun Lee; Nathan Fowler; Simrit Parmar; Jason Westin; Fredrick Hagemeister; Richard E Champlin; Stefan O Ciurea Journal: Biol Blood Marrow Transplant Date: 2019-02-11 Impact factor: 5.742
Authors: Lorenz Selberg; Peter Stadtherr; Sascha Dietrich; T Hien Tran; Thomas Luft; Ute Hegenbart; Andrea Bondong; Julia Meissner; Nora Liebers; Michael Schmitt; Anthony Dick Ho; Carsten Müller-Tidow; Peter Dreger Journal: Bone Marrow Transplant Date: 2020-06-18 Impact factor: 5.483
Authors: Peter Dreger; Anna Sureda; Kwang Woo Ahn; Mary Eapen; Carlos Litovich; Herve Finel; Ariane Boumendil; Ajay Gopal; Alex F Herrera; Christoph Schmid; José Luis Diez-Martin; Ephraim Fuchs; Javier Bolaños-Meade; Mahasweta Gooptu; Monzr M Al Malki; Luca Castagna; Stefan O Ciurea; Alida Dominietto; Didier Blaise; Fabio Ciceri; Johanna Tischer; Paolo Corradini; Silvia Montoto; Stephen Robinson; Zafer Gülbas; Mehdi Hamadani Journal: Blood Adv Date: 2019-02-12